Previous studies have suggest that anticardiolipin (aCL) antibodies can be associated with epilepsy in patients with SLE. We started a prospective study in order to determine the prevalence of aCL and anti-beta2 glycoprotein 1 (beta2-GPI) antibodies in sera of 142 patients with pediatric-onset epilepsy, without signs of autoimmunological diseases. Positive results were found in 44/142 cases (31%). We conclude that aCl and anti-beta2-GPI can be associated with epilepsy even in patients without SLE.
|Translated title of the contribution||High prevalence of anticardiolipin and/or anti-β2 glycoprotein I antibodies in young patients with epilepsy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Clinical Neurology